Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Akero Therapeutics files to sell 99.25M shares of common stock for holders  16:37
01/21/21
01/21
16:37
01/21/21
16:37
AKRO

Akero Therapeutics

$29.90 /

-0.35 (-1.16%)

 
ShowHide Related Items >><<
AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
08/31/20 B. Riley Securities
NGM released 'overwhelmingly positive' NASH update, says B. Riley FBR
AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

  • 08
    Jul
AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

Syndicate
Akero Therapeutics files to sell 1.1M shares of common stock  16:36
01/21/21
01/21
16:36
01/21/21
16:36
AKRO

Akero Therapeutics

$29.90 /

-0.35 (-1.16%)

 
ShowHide Related Items >><<
AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

11/13/20 H.C. Wainwright
Akero Therapeutics price target raised to $64 from $62 at H.C. Wainwright
10/16/20 H.C. Wainwright
Akero's PRIME designation an 'important recognition,' says H.C. Wainwright
09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
08/31/20 B. Riley Securities
NGM released 'overwhelmingly positive' NASH update, says B. Riley FBR
AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

  • 08
    Jul
AKRO Akero Therapeutics
$29.90 /

-0.35 (-1.16%)

Syndicate
Phio Pharmaceuticals announces $14M private placement priced at-the-market » 15:35
01/21/21
01/21
15:35
01/21/21
15:35
PHIO

Phio Pharmaceuticals

$3.07 /

+ (+0.00%)

Phio Pharmaceuticals…

Phio Pharmaceuticals announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $14M through the issuance of an aggregate of 4,560,928 shares of its common stock and warrants to purchase up to an aggregate of 3,420,693 shares of common stock, at a purchase price of $3.07 per share of common stock and associated warrant in a private placement priced at-the-market under Nasdaq rules. The closing of the private placement is expected to occur on or about January 25, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants have an exercise price of $3.00 per share, are exercisable immediately and have a term of five and one-half years. The company currently intends to use the net proceeds from the offering for the development of its immuno-oncology programs, other research and development activities and for general working capital needs.

ShowHide Related Items >><<
PHIO Phio Pharmaceuticals
$3.07 /

+ (+0.00%)

08/05/20
Fly Intel: Top five analyst initiations
08/05/20 H.C. Wainwright
Phio Pharmaceuticals initiated with a Buy at H.C. Wainwright
Recommendations
Praxis Precision Medicines price target raised to $61 from $51 at Wedbush » 08:21
01/21/21
01/21
08:21
01/21/21
08:21
PRAX

Praxis Precision Medicines

$56.37 /

+0.07 (+0.12%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico raised the firm's price target on Praxis Precision Medicines to $61 from $51 and keeps an Outperform rating on the shares. While Praxis investor focus remains largely on lead asset PRAX-114 in major depressive disorder, the analyst sees the pipeline offering differentiation and optionality. PRAX-562 will begin proof-of-concept studies in SUNCT/SUNA patients mid-2021, and ahead of this she is layering PRAX-562 into her estimates in the SUNCT/SUNA indication. PRAX-114 remains on track to start Phase 2/3 study efforts by the first half of 2021, Chico adds.

ShowHide Related Items >><<
PRAX Praxis Precision Medicines
$56.37 /

+0.07 (+0.12%)

PRAX Praxis Precision Medicines
$56.37 /

+0.07 (+0.12%)

11/17/20 Piper Sandler
Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
11/11/20
Fly Intel: Top five analyst initiations
11/11/20 Wedbush
Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
11/11/20 Wedbush
Praxis Precision Medicines initiated with an Outperform at Wedbush
  • 16
    Oct
PRAX Praxis Precision Medicines
$56.37 /

+0.07 (+0.12%)

Hot Stocks
Sutro Biopharma says first patient dosed in dose-expansion study of STRO-002 » 07:05
01/21/21
01/21
07:05
01/21/21
07:05
STRO

Sutro Biopharma

$26.45 /

-0.48 (-1.78%)

Sutro Biopharma announced…

Sutro Biopharma announced the dosing of the first patient in the dose-expansion cohort of the Phase 1 STRO-002 study. STRO-002 is an internally developed, folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer. The dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every 3 weeks in patients with ovarian cancer. The dose-expansion cohort for FolRalpha-selected endometrial cancer is planned for later this year.

ShowHide Related Items >><<
STRO Sutro Biopharma
$26.45 /

-0.48 (-1.78%)

STRO Sutro Biopharma
$26.45 /

-0.48 (-1.78%)

12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
STRO Sutro Biopharma
$26.45 /

-0.48 (-1.78%)

  • 09
    Dec
  • 12
    May
STRO Sutro Biopharma
$26.45 /

-0.48 (-1.78%)

STRO Sutro Biopharma
$26.45 /

-0.48 (-1.78%)

Wednesday
Hot Stocks
Dynavax appoints Kelly MacDonald as CFO » 16:07
01/20/21
01/20
16:07
01/20/21
16:07
DVAX

Dynavax

$5.13 /

+0.02 (+0.39%)

Dynavax has appointed…

Dynavax has appointed Kelly MacDonald as Senior VP and CFO. MacDonald will join the company effective March 1. CFO Michael Ostrach is retiring and has agreed to remain available as an advisor to the company thereafter. MacDonald joins Dynavax from Ironwood Pharmaceuticals where she held roles of increasing responsibility. In her final role at Ironwood MacDonald served as Chief Accounting Officer and Vice President, Finance.

ShowHide Related Items >><<
DVAX Dynavax
$5.13 /

+0.02 (+0.39%)

DVAX Dynavax
$5.13 /

+0.02 (+0.39%)

11/06/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
08/07/20 H.C. Wainwright
Dynavax price target lowered to $12 from $14 at H.C. Wainwright
08/03/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
07/16/20 William Blair
Dynavax has 'attractive asset' in CpG 1018, says William Blair
DVAX Dynavax
$5.13 /

+0.02 (+0.39%)

  • 22
    May
DVAX Dynavax
$5.13 /

+0.02 (+0.39%)

DVAX Dynavax
$5.13 /

+0.02 (+0.39%)

Tuesday
Hot Stocks
Molecular Templates announces FDA acceptance of IND for MT-6402 » 08:14
01/19/21
01/19
08:14
01/19/21
08:14
MTEM

Molecular Templates

$11.07 /

+0.01 (+0.09%)

Molecular Templates…

Molecular Templates announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with MTEM's antigen seeding technology. ETBs enabled with AST have dual mechanisms of action that include the enzymatic destruction of ribosomes and the delivery of viral class I antigens into the targeted tumor to be processed and presented on its cell surface to induce an antigen specific immune response. MTEM expects to start dosing enrolled subjects in a first-in-human Phase 1 study in relapsed/refractory patients with PD-L1-positive solid tumors in 2Q21. The Phase 1 study is planned as a multi-center, open-label, dose escalation and dose expansion trial in the United States and outside of the United States. Patients with confirmed PD-L1 expressing tumors or confirmed PD-L1 expression in the tumor microenvironment will be eligible to screen for enrollment in the clinical trial. Following determination of the maximum tolerated dose or recommended Phase 2 dose, expansion cohorts are planned to study MT-6402 as a monotherapy in tumor-specific and tumor-agnostic cohorts.

ShowHide Related Items >><<
MTEM Molecular Templates
$11.07 /

+0.01 (+0.09%)

MTEM Molecular Templates
$11.07 /

+0.01 (+0.09%)

09/08/20 Jefferies
Molecular Templates initiated with a Buy at Jefferies
08/07/20
Molecular Templates files $300M mixed securities shelf
05/12/20 Oppenheimer
Molecular Templates price target raised to $22 from $16 at Oppenheimer
03/25/20
Fly Intel: Top five analyst initiations
MTEM Molecular Templates
$11.07 /

+0.01 (+0.09%)

MTEM Molecular Templates
$11.07 /

+0.01 (+0.09%)

Hot Stocks
Atea Pharmaceuticals appoints Jayanthi Wolf as SVP, regulatory affairs » 07:20
01/19/21
01/19
07:20
01/19/21
07:20
AVIR

Atea Pharmaceuticals

$53.27 /

+1.11 (+2.13%)

, MRK

Merck

$83.40 /

+1.225 (+1.49%)

Atea Pharmaceuticals…

Atea Pharmaceuticals (AVIR) announced that it has expanded its senior management team with the appointments of Jayanthi Wolf, Ph.D., SVP of Regulatory Affairs and Jonae Barnes, SVP of Investor Relations and Corporate Communications. Wolf has had an extensive career in research and development at Merck (MRK) over a 19-year period. During her tenure at Merck, she served in a series of roles ranging from scientific to safety assessment and regulatory, with increasing responsibility in global regulatory affairs and clinical safety. Ms. Barnes served most recently as SVP, Investor Relations, Corporate Communications and Internal Communications at Sunovion.

ShowHide Related Items >><<
MRK Merck
$83.40 /

+1.225 (+1.49%)

AVIR Atea Pharmaceuticals
$53.27 /

+1.11 (+2.13%)

AVIR Atea Pharmaceuticals
$53.27 /

+1.11 (+2.13%)

11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
11/24/20 Morgan Stanley
Atea Pharmaceuticals initiated with an Overweight at Morgan Stanley
11/24/20 JPMorgan
Atea Pharmaceuticals initiated with an Overweight at JPMorgan
11/24/20 William Blair
William Blair starts Atea Pharmaceuticals with Outperform, $60 fair value
MRK Merck
$83.40 /

+1.225 (+1.49%)

01/06/21 Citi
Citi opens 'positive catalyst watch' on Merck
01/05/21 Citi
Citi boosts Merck target to $105, says may be most undervalued in pharma
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
12/21/20 Alliance Global Partners
Alliance Global Partners keeps Buy on Sellas following data from trials
MRK Merck
$83.40 /

+1.225 (+1.49%)

  • 30
    Oct
MRK Merck
$83.40 /

+1.225 (+1.49%)

MRK Merck
$83.40 /

+1.225 (+1.49%)

AVIR Atea Pharmaceuticals
$53.27 /

+1.11 (+2.13%)

MRK Merck
$83.40 /

+1.225 (+1.49%)

Hot Stocks
Chiasma appoints John Doyle as CFO » 07:17
01/19/21
01/19
07:17
01/19/21
07:17
CHMA

Chiasma

$3.92 /

-0.02 (-0.51%)

, VSTM

Verastem

$2.45 /

+0.02 (+0.82%)

Chiasma (CHMA) announced…

Chiasma (CHMA) announced the hiring of John Doyle as its new CFO. As previously reported, Mark Fitzpatrick, Chiasma's current President and Principal Financial Officer, will remain with the company in a consulting role through June 30, 2021 to help facilitate a transition of responsibilities to Mr. Doyle. Prior to joining Chiasma, Mr. Doyle served as VP of Finance and Investor Relations at Verastem (VSTM).

ShowHide Related Items >><<
VSTM Verastem
$2.45 /

+0.02 (+0.82%)

CHMA Chiasma
$3.92 /

-0.02 (-0.51%)

CHMA Chiasma
$3.92 /

-0.02 (-0.51%)

01/11/21 Piper Sandler
Chiasma price target lowered to $15 from $19 at Piper Sandler
11/05/20 Piper Sandler
Chiasma reports first Mycapssa sales, strong cash balance, says Piper Sandler
08/31/20 Piper Sandler
Piper sees strong demand for Chiasma's oral acromegaly therapy
08/13/20 Jefferies
Chiasma initiated with a Buy at Jefferies
VSTM Verastem
$2.45 /

+0.02 (+0.82%)

04/27/20 JonesTrading
Verastem downgraded to Hold from Buy at JonesTrading
04/23/20 Cantor Fitzgerald
Verastem's market cap could double with positive data, says Cantor Fitzgerald
03/20/20 JonesTrading
Verastem upgraded to Buy from Hold at JonesTrading
03/03/20 Cantor Fitzgerald
Verastem price target raised to $6 from $3 at Cantor Fitzgerald
VSTM Verastem
$2.45 /

+0.02 (+0.82%)

CHMA Chiasma
$3.92 /

-0.02 (-0.51%)

  • 01
    Jul
CHMA Chiasma
$3.92 /

-0.02 (-0.51%)

VSTM Verastem
$2.45 /

+0.02 (+0.82%)

Hot Stocks
C4 Therapeutics announces FDA clearance for CFT7455 IND application » 07:03
01/19/21
01/19
07:03
01/19/21
07:03
CCCC

C4 Therapeutics

$38.53 /

+0.64 (+1.69%)

C4 Therapeutics announced…

C4 Therapeutics announced that the U.S. Food and Drug Administration has cleared the company's investigational new drug application for its lead product candidate, CFT7455, an orally bioavailable MonoDAC targeting IKZF1/3 for the treatment of hematologic malignancies such as multiple myeloma and non-Hodgkin lymphomas, including peripheral T cell lymphoma and mantle cell lymphoma. The FDA has completed its 30-day safety review and granted approval for the company to proceed with the proposed Phase 1/2 clinical trial for CFT7455. The Phase 1/2 clinical trial will be an open-label, two-part dose-escalation and expansion study evaluating CFT7455 across multiple hematologic malignancies. The Phase 1 portion of the trial will explore CFT7455 as a single agent in patients with relapsed or refractory multiple myeloma and non-Hodgkin lymphomas, and in parallel in combination with dexamethasone in R/R MM patients. Following the identification of an optimal dose, the Phase 2 expansion portion of the trial will enroll additional investigational arms including patients with MM, as single agent and in combination with dexamethasone, and as single agent in patients with mantle cell lymphoma and peripheral T-cell lymphoma, two subtypes of NHL. The trial will primarily investigate safety and tolerability, with key secondary objectives to characterize the pharmacokinetic and pharmacodynamic profile and anti-tumor activity of CFT7455.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.53 /

+0.64 (+1.69%)

CCCC C4 Therapeutics
$38.53 /

+0.64 (+1.69%)

12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
10/28/20 UBS
C4 Therapeutics initiated with a Buy at UBS
10/27/20 Jefferies
C4 Therapeutics initiated with a Buy at Jefferies
  • 02
    Oct
CCCC C4 Therapeutics
$38.53 /

+0.64 (+1.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.